Elevating Biomanufacturing Efficiency with N-1 Perfusion Technology

In the dynamic world of biomanufacturing, the quest for improved efficiency and productivity continues to shape industry advancements. Among these innovations, the emergence of N-1 perfusion technology stands out as a pivotal milestone, offering a practical pathway to enhance production processes and boost overall efficiency.

N-1 perfusion operates on a simple yet powerful principle known as process intensification. This strategic approach aims to maximise the output of manufacturing facilities and streamline the timelines of production. While continuous processing has garnered attention for its efficiency gains, the traditional fed-batch culture remains a fundamental method in stable protein production using mammalian cell culture. In this context, techniques to intensify fed-batch processes, such as N-1 perfusion, present exciting opportunities for the advancement of biomanufacturing practices.

The appeal of N-1 perfusion lies in its ability to support high cell densities with sustained exponential growth and viability. This capability extends beyond the production phase to include the critical aspect of seed train intensification – a fundamental process in bioprocessing. By enabling a significant increase in cell density, N-1 perfusion offers a way to streamline operations by reducing the size or number of required seed reactors, thereby optimising facility space and investment costs. At the heart of this strategy is the concept of seeding the fed-batch production bioreactor with substantially higher cell densities from the N-1 seed culture. This strategic shift in the early growth phase of production paves the way for streamlined timelines without compromising the essential growth and yield profiles of the final product.

In this article, we delve into the practical applications of N-1 perfusion technology, showcasing its potential to transform biomanufacturing processes. Through real-world examples and data, we demonstrate how N-1 perfusion enables facilities to achieve higher productivity and improved efficiency – all while optimising resource utilisation and operational costs. Let's now break down the discussion into key aspects of N-1 perfusion technology, exploring its suitability for various processes and products, considerations for implementation, its rising adoption in the industry, and future directions.

Suitable Processes and Products for N-1 Perfusion

N-1 (seed) intensification through perfusion technology proves highly beneficial where the goal is to enhance productivity without major alterations to the production process. The essence of N-1 perfusion lies in increasing the cell density in the pre-production bioreactor, denoted as N-1 (N being the production bioreactor). This increase in cell density is achieved more effectively using perfusion technology compared to routine batch modes. This intensification strategy is applicable to a wide range of cell lines and products, provided the cell line can achieve high densities while maintaining viability.

Processes or Products Not Ideal for N-1 Perfusion

In the realm of biologics, most things are not a one-size-fits-all solution. While N-1 perfusion can theoretically be applied to any process, a critical cost-benefit analysis is key. The potential efficiency gains of N-1 perfusion must be weighed against the costs of goods, initial capital investments for equipment, site maintenance, and process development. Furthermore, the enhancement in titer must align with efficient downstream processes to improve overall facility throughput and reduce the cost per gram of product manufacturing.

Increasing Adoption of N-1 Perfusion

Interest in N-1 perfusion has been steadily growing over the years, especially among manufacturers facing specific challenges in meeting market demands. The allure of quick entry into clinical trials, coupled with established knowledge and platform processes such as fed-batch, often prompts the initial choice. Subsequently, the evaluation of intensification options occurs as product requirements become clearer through clinical studies. Notably, N-1 perfusion can be integrated into existing Fed-Batch processes with minimal modifications, avoiding a complete overhaul of infrastructure. However, maintaining product quality attributes remains paramount to successful adoption.

N-1 Perfusion in Continuous Bioreactors

N-1 perfusion primarily serves as a seed-stage intensification method and may not directly translate to continuous production batch operations. Continuous manufacturing scenarios are better suited for N perfusion.

Impact on Reactor Scales and Productivity

Intensification through N-1 perfusion results in a 2-3-fold improvement in titer, enabling significantly higher throughput

from existing production bioreactors. A 2kL reactor, for instance, can achieve the productivity equivalent of a 4kL or 6kL reactor through this method.

Product Purity in Perfused Systems
The final product's purity remains comparable to that of traditional fed-batch processes, despite continuous by-product removal in perfusion systems.

Future Developments
Future advancements in N-1 perfusion may involve the integration of Process Analytical Technology (PAT) tools and enhanced downstream processing. The combination of these technologies could further amplify the advantages of N-1 perfusion, improving efficiency and product quality.

Clinical Phase Considerations
N-1 perfusion technology is versatile and can be implemented at any phase of product clinical trials. While Phase 3 is a common starting point, early adoption prior to Phase 1 offers earlier benefits and reduces the risk of future process changes.

Adoption in CDMOs
Not all CDMOs currently offer N-1 perfusion due to its nuanced nature. Developing the optimal media combination to sustain higher cell densities and boost productivity requires specific optimization with individual cell line platforms.

Syngene's Success with N-1 Perfusion
Syngene has showcased the effectiveness of N-1 perfusion with multiple monoclonal antibodies, achieving titer improvements of 2-3 folds compared to conventional fed-batch processes. This has resulted in impressive titers of up to 12 g/L.

Conclusion
The rise of N-1 perfusion technology marks a significant step forward in biomanufacturing, offering a practical and efficient approach to improve productivity and product quality. Through this discussion, we have explored the various ways in which N-1 perfusion enhances production processes and streamlines operations. The core benefit of N-1 perfusion lies in its ability to intensify the seed train process by supporting high-density cell cultures. This means quicker production timelines, reduced facility costs, and increased efficiency without compromising the quality of the final product. Looking ahead, the potential for N-1 perfusion technology is vast. Its integration with emerging tools like Process Analytical Technology (PAT) and continuous downstream processing promises even greater efficiency gains and innovation in biomanufacturing. As exemplified by the success stories of Syngene and other industry pioneers, N-1 perfusion stands as a testament to the continual advancement of bioprocessing techniques. With further research and adoption, N-1 perfusion is poised to reshape the biopharmaceutical landscape, setting new standards for productivity and quality.

Sridevi Khambhampaty

Sridevi holds an MSc in Biotechnology and a doctorate in Biological Sciences. She completed her postdoctoral fellowship at Stanford University School of Medicine, focusing on cell biology. With over 20 years of experience, Sridevi has led bioanalytical and quality control departments, focusing on assessing protein therapeutics through in vitro and in vivo methods, including functional characterisation, pharmacokinetics, pharmacodynamics and immunogenicity evaluations. Furthermore, Sridevi has managed teams responsible for conducting lot release bioassays and validating analytical methods, encompassing areas like HPLC, biochemistry, cell-based bioassay and microbiology. She also oversaw stability studies within these roles. Sridevi's career includes leadership positions at Dr Reddy's Laboratories and Intas Pharmaceuticals Ltd. Currently serving as Vice President at Syngene International Limited, she oversees biopharmaceutical production. In this role, Sridevi is responsible for optimising processes, ensuring regulatory compliance, and driving innovation in manufacturing.